Physician profile
Kirk Elliott
NPI 1639104169
$1,235.30
in general payments reported to CMS, 2019-2025
23 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $19.66 · 2021: $16.66 · 2022: $163 · 2023: $258 · 2024: $214 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $860.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $261.46 | 2019-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $94.40 | 2024-2025 | Airsupra |
| Viatris Specialty LLC | $89.78 | 2025 | Yupelri |
| Lilly USA, LLC | $85.22 | 2023-2025 | Mounjaro |
| Pfizer INC. | $78.97 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $76.83 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.26 | 2024-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.74 | 2019-2025 | Xifaxan |
| Abbvie INC. | $57.14 | 2023-2025 | |
| Novo Nordisk INC | $49.02 | 2023-2025 | Rybelsus, Ozempic |
| Phathom Pharmaceuticals, INC. | $45.65 | 2023-2024 | Voquezna |
| Cepheid | $41.72 | 2025 | Genexpert |
| Ardelyx, INC. | $34.98 | 2024-2025 | Ibsrela |
| Amgen INC. | $30.38 | 2019-2025 | Repatha, Otezla |
| Abbott Laboratories | $20.98 | 2023 | Freestyle Libre 3 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $17.90 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $17.88 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.70 | 2024 | Caplyta |
| Idorsia Pharmaceuticals US INC | $17.55 | 2022 | |
| Exact Sciences Corporation | $16.47 | 2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $15.41 | 2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $14.99 | 2019 | |
| Glaxosmithkline, LLC. | $14.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.